John S Tokarski

This inventor holds 37 USPTO granted patents and 12 published patent applications, plus 4 CIPO patents and 19 EPO patents, primarily in Heterocyclic Compounds. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2003-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John S Tokarski. Retrieved from https://idiyas.com/inventor/john-s-tokarski

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 37 (Patent Applications = 12)

% Patents Active = 97.3

CIPO Patents = 4 (Patent Applications = 6)

EPO Patents = 19 (Patent Applications = 21)

Average Co-Inventor Count = 8.0

ph-index = 10

Forward Citations = 262(Granted Patents)

Company Filing History:

37 out of 3,742

Bristol-Myers Squibb Compnay

patents

Years Active: 2003-2025

Loading Chart...

Areas of Expertise:

Heteroaryl Compounds

T Cell Activators

Kinase Inhibitors

Bromodomain Inhibitors

Tricyclic Compounds

Amide-Substituted Compounds

Pyridazine Compounds

Cannabinoid Receptor Modulators

Anticancer Agents

Inflammatory Diseases

IL-12 Modulators

Androgen Receptor

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12365667 - Sulfone pyridine alkyl amide-substituted heteroaryl compounds (2025-07-22),

2. 12037323 - Uracil derivatives as Mer-AXL inhibitors (2024-07-16),

3. 11787779 - Sulfone pyridine alkyl amide-substituted heteroaryl compounds (2023-10-17),

4. 11713316 - Substituted naphthyridinone compounds useful as T cell activators (2023-08-01),

5. 11021462 - Sulfone pyridine alkyl amide-substituted heteroaryl compounds (2021-06-01),

6. 10954238 - Substituted naphthyridinone compounds useful as T cell activators (2021-03-23),

7. 10669272 - Substituted naphthyridinone compounds useful as T cell activators (2020-06-02),

8. RE47929 - Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses (2020-04-06),

9. 10273237 - Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses (2019-04-30),

10. 10196387 - Carbazole compounds useful as bromodomain inhibitors (2019-02-05),

11. 10112941 - Tricyclic compounds as anticancer agents (2018-10-30),

12. 10053454 - Carbazole compounds useful as bromodomain inhibitors (2018-08-21),

13. 10000480 - Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses (2018-06-19),

14. 9987266 - Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses (2018-06-05),

15. 9751879 - Tricyclic compounds as anticancer agents (2017-09-05),

Title: **John S. Tokarski: Innovator in Pharmaceutical Compounds**

Introduction

John S. Tokarski, based in Princeton, NJ, is a prominent inventor with an impressive portfolio of 36 patents. His work primarily focuses on the development of innovative pharmaceutical compounds that address significant medical challenges. Tokarski's recent inventions showcase his commitment to advancing medical science, particularly in the fields of oncology and immunology.

Latest Patents

Among his latest patents, one highlights the invention of Uracil derivatives as Mer-AXL inhibitors. This invention involves novel compounds that act as inhibitors of the Mer-Axl pathway, which is crucial for treating proliferative disorders and dysregulated apoptosis, including various forms of cancer. Another notable patent involves sulfone pyridine alkyl amide-substituted heteroaryl compounds, which are designed to modulate IL-12, IL-23, and/or IFNα by targeting Tyk-2 to inhibit signal transduction. These innovative compounds represent significant strides in therapeutic development.

Career Highlights

John S. Tokarski is currently employed at Bristol-Myers Squibb Company, a leading biopharmaceutical firm that specializes in discovering, developing, and delivering innovative medicines. His extensive background and contributions to the company emphasize the impactful nature of his research and innovations.

Collaborations

Throughout his career, Tokarski has collaborated with notable colleagues, including Stephen T. Wrobleski and Ashvinikumar V. Gavai. These partnerships highlight the importance of teamwork in driving forward scientific discoveries and fostering innovation in the pharmaceutical industry.

Conclusion

In conclusion, John S. Tokarski stands out as a significant contributor to the field of pharmaceuticals, exemplified by his numerous patents and collaborations. His work at Bristol-Myers Squibb Company continues to shape the landscape of medical treatments, making substantial impacts on patient care and treatment options. As he further explores groundbreaking compounds, the medical community can look forward to his continued contributions to innovation in healthcare.

Profile summary based on public USPTO records.